Perspective Therapeutics, Inc.CATX
Price (close)
$2.52
Market cap
$287.5M
P/E
—
Revenue (TTM)
—
Net income
-$116.4M
Dividend yield
—
1-year total return
-21.0%
Net margin
—
Revenue growth
—
Debt / equity
0.00x
What Perspective Therapeutics, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | $0 | $1.4M | — | — |
| Net income | — | — | -$10.8M | -$46.5M | -$79.3M | -$103.1M |
| Free cash flow | — | — | -$10.7M | -$38.0M | -$72.7M | -$95.2M |
More on CATX.
- Perspective Therapeutics, Inc. summary
- Perspective Therapeutics, Inc. financial statements
- Perspective Therapeutics, Inc. key metrics
- Perspective Therapeutics, Inc. health scores and style box
- Perspective Therapeutics, Inc. earnings
- Perspective Therapeutics, Inc. dividends
- Perspective Therapeutics, Inc. valuation
- Perspective Therapeutics, Inc. ownership and insiders
- Perspective Therapeutics, Inc. peers
Figures from Perspective Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.